Aethlon Medical Stock Price, News & Analysis

Aethlon Medical, Inc. (Nasdaq: AEMD) has announced a partnership with PPD, Inc. (Nasdaq: PPD) to manage clinical studies for its Hemopurifier, a therapeutic blood filtration system focused on treating infectious diseases, including COVID-19. Under this agreement, PPD will oversee ongoing clinical trials and may expand to additional studies. The Hemopurifier has received FDA Breakthrough Device designation and has shown promise in removing harmful viruses and exosomes in prior studies. This collaboration aims to expedite the clinical development for critically ill patients.

Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. CEO Charles J. Fisher will offer an overview on September 13 at 7:00 AM EDT, available on-demand for 90 days. Aethlon’s Hemopurifier, a clinical-stage device for treating cancer and viral infections, holds FDA's Breakthrough Device designation. The company also operates Exosome Sciences, focused on exosomal biomarkers for cancer and neurological diseases.

Aethlon Medical, Inc. (Nasdaq: AEMD) reported financial results for Q1 ended June 30, 2021, highlighting continued clinical development of the Hemopurifier for COVID-19. The company raised $17.5 million from common stock sales, bringing cash reserves to $25.2 million. Total government contract revenue was approximately $132,000. Operating expenses increased to $2.2 million, leading to a net loss of $2.1 million, up from $1.4 million year-over-year. The company is negotiating with additional clinical centers for trials, with a focus on potential treatments for SARS-CoV-2.

Aethlon Medical, Inc. (AEMD) will announce its first quarter fiscal year 2022 financial results on August 9, 2021, at 4:15 p.m. EST. This will be followed by a conference call at 4:30 p.m. EST to discuss the results and recent corporate developments. The company is known for its Hemopurifier®, a medical device addressing unmet global health needs, particularly in cancer treatment and life-threatening viral infections like COVID-19. The Hemopurifier has received FDA 'Breakthrough Device' designation, allowing for innovative clinical applications and studies.

Aethlon Medical (AEMD) reported financial results for the fiscal year ended March 31, 2021, highlighting a net loss of approximately $7.9 million, up from $6.4 million the previous year. Operating expenses increased to about $8.6 million, driven by higher payroll and clinical trial costs. The company raised around $17.3 million in June 2021 through various financing methods. The Aethlon Hemopurifier showed potential in treating COVID-19 patients, with successful case studies reported. As of March 31, 2021, cash reserves stood at about $9.9 million.

Aethlon Medical (AEMD) will release its financial results for Q4 fiscal year 2021 on June 24, 2021, at 4:15 p.m. ET. Management will also host a conference call at 4:30 p.m. ET the same day to discuss the results and corporate developments. The Hemopurifier, the company’s clinical-stage device, aims to treat cancer and viral infections. It holds FDA designations as a Breakthrough Device for advanced cancer and life-threatening viral infections, including COVID-19.

Aethlon Medical, Inc. (Nasdaq:AEMD) announced a registered direct offering of 1,380,555 shares at $9.00 per share, totaling approximately $12.425 million in gross proceeds. The offering is expected to close on June 14, 2021. Proceeds will be used for working capital and general corporate purposes. Additionally, Aethlon sold 626,000 shares under its At the Market Offering Agreement and will issue 1.12 million shares due to warrant exercises. The Hemopurifier, a key product, is in clinical trials for cancer treatment and COVID-19.

Aethlon Medical (Nasdaq: AEMD) announced a pre-print manuscript detailing two case studies of critically ill COVID-19 patients treated with the Hemopurifier® via Emergency Use. The first patient showed recovery signs despite previous severe viremia and achieved hospital discharge after eight treatments. The second patient demonstrated the in vivo removal of SARS-CoV-2 but unfortunately expired due to disease severity. The company is conducting an Early Feasibility Study, aiming to enroll 40 ICU COVID-19 patients. The Hemopurifier is recognized as a Breakthrough Device for both cancer and life-threatening viral infections.

Aethlon Medical, Inc. (Nasdaq: AEMD) announced its participation in two virtual conferences: the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021, and the Maxim Group and M Vest 2021 Emerging Growth Virtual Conference on March 17-18, 2021.

The company’s presentations will include details on the Aethlon Hemopurifier, a device aimed at cancer treatment and viral infections, which holds FDA Breakthrough Device designation. Webcasts will be available on demand starting March 9 at 7:00 a.m. EST.